Keywords: reports, cv, toxicity, emerge, novartis, wonder, anticancer

Reports of CV toxicity emerge for Novartis' "wonder" anticancer drug Gleevec

Article | 31 July 2006

Print This

New data published in the journal Nature Medicine suggest that Novartis'Gleevec (imatinib mesylate; sold in Europe as Glivec) may lead ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in